Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H17NO.ClH |
Molecular Weight | 215.72 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@H]([C@@H](O)C1=CC=CC=C1)N(C)C
InChI
InChIKey=NTCYWJCEOILKNG-FOKYBFFNSA-N
InChI=1S/C11H17NO.ClH/c1-9(12(2)3)11(13)10-7-5-4-6-8-10;/h4-9,11,13H,1-3H3;1H/t9-,11-;/m1./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2327112Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9681334
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1310.12
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2327112
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9681334
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1310.12
Methylephedrine is one of the ephedra alkaloids that is found in varying amounts in different species of the plant genus Ephedra. Methylephedrine is a popular antitussive, bronchodilator, analgesic, antipyretic, and widely used mixed with other drugs in preparations for treatment of the common cold. N-Methylephedrine, its salts, optical isomers, and salts of optical isomers are in FDA list of Exempt chemical mixtures.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Histamine receptors Sources: https://www.ncbi.nlm.nih.gov/pubmed/8990487 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Sanwa Approved UseIt is usually used in the treatment of cough associated with diseases such as bronchial asthma, cold, acute or chronic bronchitis, pulmonary tuberculosis, and upper airway inflammation. |
Sample Use Guides
Take 0.25-0.5 g (25-50 mg of the active ingredient) at a time, 3 times daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8910253
l-MEP inhibited the twitch response at high concentrations (3 x 10(-5)-10(-3) M). On the other hand, d-MEP showed the potentiation of twitch response, and competitively antagonized the twitch-inhibitory effect of clonidine (10(-9)-10(-6) M) with the pA2 value of 4.3 in the presence of prazosin.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P982XVV768
Created by
admin on Sat Dec 16 04:36:33 GMT 2023 , Edited by admin on Sat Dec 16 04:36:33 GMT 2023
|
PRIMARY | |||
|
656696
Created by
admin on Sat Dec 16 04:36:33 GMT 2023 , Edited by admin on Sat Dec 16 04:36:33 GMT 2023
|
PRIMARY | |||
|
54114-10-2
Created by
admin on Sat Dec 16 04:36:33 GMT 2023 , Edited by admin on Sat Dec 16 04:36:33 GMT 2023
|
PRIMARY | |||
|
DTXSID00202461
Created by
admin on Sat Dec 16 04:36:33 GMT 2023 , Edited by admin on Sat Dec 16 04:36:33 GMT 2023
|
PRIMARY | |||
|
m7410
Created by
admin on Sat Dec 16 04:36:33 GMT 2023 , Edited by admin on Sat Dec 16 04:36:33 GMT 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD